National academy

PFAS ‘forever chemicals’: Why EPA set federal drinking water limits for these health-harming contaminants

Retrieved on: 
Wednesday, April 10, 2024

The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.

Key Points: 
  • The U.S. Environmental Protection Agency now believes there is no safe level for two common PFAS – PFOA and PFOS – in drinking water, and it acknowledges that very low concentrations of other PFAS present human health risks.
  • The agency issued the first legally enforceable national drinking water standards for five common types of PFAS chemicals, as well as PFAS mixtures, on April 10, 2024.

What exactly are PFAS?

  • This is a large group of human-made chemicals – currently estimated to be nearly 15,000 individual chemical compounds – that are used widely in consumer products and industry.
  • They can make products resistant to water, grease and stains and protect against fire.
  • The short answer is that PFAS are harmful to human health and the environment.
  • Some of the very same chemical properties that make PFAS attractive in products also mean these chemicals will persist in the environment for generations.
  • The U.S. Geological Survey estimates common types of PFAS are now in at least 45% of the country’s tap water.

What are the health risks from PFAS exposure?

  • Research consistently demonstrates that PFAS are associated with a variety of adverse health effects.
  • A review by a panel of experts looking at research on PFAS toxicity concluded with a high degree of certainty that PFAS contribute to thyroid disease, elevated cholesterol, liver damage, and kidney and testicular cancer.
  • Additionally, current research suggests that babies exposed prenatally are at higher risk of experiencing obesity, early-onset puberty and reduced fertility later in life.
  • Collectively, this is a formidable list of diseases and disorders.

Who’s regulating PFAS?

  • DuPont called it Teflon, which eventually became a household name for its use on nonstick pans.
  • Decades later, in 1998, Scotchgard maker 3M notified the Environmental Protection Agency that a PFAS chemical was showing up in human blood samples.
  • At the time, 3M said low levels of the manufactured chemical had been detected in people’s blood as early as the 1970s.
  • The Agency for Toxic Substances and Disease Registry has a toxicological profile for PFAS.

How can you reduce your PFAS exposure?

  • The best ways to protect yourself and your family from risks associated with PFAS are to educate yourself about potential sources of exposure.
  • Products labeled as water- or stain-resistant have a good chance of containing PFAS.
  • Strategies for monitoring and reporting PFAS contamination vary by location and PFAS source, so the absence of readily available information does not necessarily mean the region is free of PFAS problems.


Kathryn Crawford receives funding from National Institutes of Health and US Geological Survey.

Minerals Technologies Announces Election of Kristina M. Johnson to Board of Directors

Retrieved on: 
Tuesday, March 26, 2024

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.

Key Points: 
  • NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI” or “the Company”) today announced that Kristina M. Johnson has been elected to its Board of Directors.
  • “We are excited to welcome Kristina Johnson to our Board,” said Douglas T. Dietrich, Chairman and Chief Executive Officer.
  • She currently serves on the boards of DuPont and Cisco Systems, Inc., and previously served on the Minerals Technologies Inc. Board from 2000 to 2009.
  • Dr. Johnson will begin her service on the MTI Board of Directors on May 13, 2024.

Cox Media Group Promotes Marian Pittman To President of Content & WSB-TV

Retrieved on: 
Tuesday, March 26, 2024

ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Cox Media Group (CMG) announced today that Marian Pittman will expand her responsibilities to include leading WSB-TV.

Key Points: 
  • ATLANTA, March 26, 2024 (GLOBE NEWSWIRE) -- Cox Media Group (CMG) announced today that Marian Pittman will expand her responsibilities to include leading WSB-TV.
  • Pittman, who currently leads CMG’s Content, Product, Innovation and Research teams, will be promoted to President of Content & WSB-TV.
  • Pittman is one of the broadcast media industry’s most innovative and successful leaders.
  • She currently spearheads the ongoing evolution of the company’s streaming and digital business, including multi-platform and award-winning content.

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

NVIDIA Blackwell Platform Arrives to Power a New Era of Computing

Retrieved on: 
Monday, March 18, 2024

The NVIDIA GB200 Grace Blackwell Superchip connects two NVIDIA B200 Tensor Core GPUs to the NVIDIA Grace CPU over a 900GB/s ultra-low-power NVLink chip-to-chip interconnect.

Key Points: 
  • The NVIDIA GB200 Grace Blackwell Superchip connects two NVIDIA B200 Tensor Core GPUs to the NVIDIA Grace CPU over a 900GB/s ultra-low-power NVLink chip-to-chip interconnect.
  • It combines 36 Grace Blackwell Superchips, which include 72 Blackwell GPUs and 36 Grace CPUs interconnected by fifth-generation NVLink.
  • The Blackwell product portfolio is supported by NVIDIA AI Enterprise , the end-to-end operating system for production-grade AI.
  • To learn more about the NVIDIA Blackwell platform, watch the GTC keynote and register to attend sessions from NVIDIA and industry leaders at GTC, which runs through March 21.

Nathan Kuppermann, M.D., M.P.H., named chief academic officer and chair of Pediatrics at Children’s National Hospital

Retrieved on: 
Wednesday, March 13, 2024

Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.

Key Points: 
  • Washington, D.C., March 13, 2024 (GLOBE NEWSWIRE) -- Children's National Hospital has appointed Nathan Kuppermann, M.D., M.P.H., as its new executive vice president (EVP), chief academic officer (CAO) and chair of Pediatrics.
  • He comes to Children’s National from UC Davis Health and UC Davis School of Medicine in Sacramento, CA, and will start in September.
  • After a national search, Dr. Kuppermann stood out for his exceptional contributions to clinical and academic research, focusing on pediatric emergency care, and his dedication to mentorship.
  • He completed a pediatrics residency and chief residency at Harbor-UCLA Medical Center and a fellowship in Pediatric Emergency Medicine at Boston Children's Hospital.

GPCR Therapeutics Announces Publication in PNAS Using Cutting Edge Spectroscopy to Detect GPCR Heteromers on Live Cancer Cells

Retrieved on: 
Monday, April 1, 2024

This research underscores the company’s commitment to targeting diseases with cutting-edge approaches against GPCRs and discovering novel therapeutics.

Key Points: 
  • This research underscores the company’s commitment to targeting diseases with cutting-edge approaches against GPCRs and discovering novel therapeutics.
  • Detection of multimeric complexes by CXCR4 with other GPCRs in a live-cell environment validates the dual GPCR targeting hypothesis.
  • The work uses time-resolved fluorescence spectroscopy to quantify CXCR4 and β2AR interactions as they form complexes in live cells under physiological conditions.
  • Dr. Dong Seung Seen, Founder and CEO of GPCR Therapeutics based in Seoul, spoke about Dr. Caculitan’s accomplishments.

Politan Nominates Two Independent Candidates for Masimo Board

Retrieved on: 
Monday, March 25, 2024

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).

Key Points: 
  • Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), today announced that it is nominating two candidates for election to the Masimo Board of Directors (the “Board”) at the upcoming 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
  • Quentin Koffey, Managing Partner and Chief Investment Officer of Politan, and a current director on the Masimo Board, stated:
    “When shareholders overwhelmingly elected Michelle Brennan and me to the Masimo Board last year, we were optimistic we could work productively with the rest of the Board to drive positive change.
  • However, at this stage the Board has been provided zero details, and Politan has serious concerns given the lack of basic governance and oversight we have observed since joining the Board.
  • The participants in the proxy solicitation are Politan, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, Politan Capital NY LLC, Politan Intermediate Ltd., Politan Capital Partners Master Fund LP (“Politan Master Fund”), Politan Capital Partners LP (“Politan LP”), Politan Capital Offshore Partners LP (“Politan Offshore” and collectively with Politan Master Fund and Politan LP, the “Politan Funds”), Quentin Koffey, Matthew Hall, Aaron Kapito, William Jellison and Darlene Solomon (collectively, the “Participants”).

Bioelectronic medicine Feinstein Institutes researchers elected to AIMBE College of Fellows

Retrieved on: 
Monday, March 25, 2024

The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.

Key Points: 
  • The American Institute for Medical and Biological Engineering (AIMBE) has announced the election of two researchers from The Feinstein Institutes for Medical Research to the AIMBE College of Fellows Class of 2024 for their contributions to the fields of medical and biological engineering, and particularly the field of bioelectronic medicine.
  • Valentin Pavlov, PhD , and Sangeeta Chavan, PhD , both professors in the Institute of Bioelectronic Medicine , were recognized in-person during the AIMBE Annual Event in Washington D.C..
  • Sangeeta Chavan (left) and Valentin Pavlov (right) have been elected to the AIMBE College of Fellows for advancing the fields of medical and biological engineering.
  • On behalf of the Feinstein Institutes and Northwell Health, we congratulate them.”
    The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine where medical researchers use modern technology to develop new device-based therapies to treat disease and injury.